Proprietary Nasal Delivery Formulation of Diazepam Developed by Particle Sciences Reaches NDA
CLEVELAND, Ohio, Nov, 05 2018 - (ACN Newswire) - The Lubrizol Corporation announces a proprietary nasal delivery formulation of diazepam for the treatment of epilepsy which was developed by contract development and manufacturing organization (CDMO), Particle Sciences, a Lubrizol LifeSciences company, has been submitted as a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by San Diego-based Neurelis Inc.
VALTOCO(TM), previously referred to in clinical development as 'NRL-1', is the lead product candidate of Neurelis, worked closely with Particle Sciences on the formulation of the diazepam nasal spray designed to treat acute repetitive seizures in patients over the age of six.
Using its DOSE(R) platform that combines empirically obtained data with customized solubility software based on Hansen solubility parameters, Particle Sciences was able to achieve extremely high levels of solubilized diazepam using a benign vehicle that is compatible with nasal delivery. The resulting absolute bioavailability of the VALTOCO intranasal formulation was 96% of intravenous diazepam in a Phase 1 cross-over trial of healthy volunteers.
The NDA for VALTOCO is a 505(b)(2) filing utilizing rectal diazepam gel, the only current FDA approved therapeutic product for home treatment of acute repetitive seizures, as the Reference Listed Drug. The NDA is supported by further extensive clinical studies in healthy volunteers and patients with epilepsy, with more than 1,600 seizures treated to date with the nasal spray.
Dr. Robert Lee, president of Particle Sciences states, "It's rewarding to see VALTOCO reach this key milestone after Neurelis' successful clinical trials. This product will bring positive improvements to the lives of many patients with acute repetitive seizures."
Lee adds, "Nasal delivery is often an overlooked route of administration but can offer an ideal path and increase bioavailability for several drug types, particularly those designed to treat diseases of the central nervous system. We are seeing real growth in this area and expect to see an increase in demand for nasal formulations in the future as we continue to focus on the development of complex drug products."
Craig Chambliss, president and CEO of Neurelis comments, "Having assessed dozens of formulation approaches for solving the challenges with delivering intranasal benzodiazepines for epilepsy patients, we partnered with Particle Sciences to leverage their experience and expertise in solving for a formulation issue that has kept poorly soluble drugs from being developed for significant unmet clinical needs."
According to the Centers for Disease Control and Prevention, there are more than 3.4 million people with epilepsy in the United States with approximately 200,000 new patients diagnosed each year. Despite the availability of chronic, daily oral medications to control epilepsy, a significant number of these patients continue to experience seizures. Of these uncontrolled patients, about 170,000 are at risk for cluster or acute repetitive seizures.
Particle Sciences will be exhibiting at this year's American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 November 4 - 7 on stand #2319.
Particle Sciences is part of Lubrizol Advanced Materials Inc.
About Particle Sciences
Particle Sciences, a Lubrizol LifeSciences company, is an integrated provider of drug development services. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Particle Sciences is FDA registered and DEA licensed. Through a full range of formulation, analytic and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.
About Lubrizol LifeSciences
Lubrizol LifeSciences is a preferred Contract Development and Manufacturing Organization (CDMO) partner for complex pharmaceuticals and high-end medical devices providing differentiated polymers and excipients, along with state-of-the-art design, development and manufacturing services to the healthcare industry.
About The Lubrizol Corporation
The Lubrizol Corporation, a Berkshire Hathaway company, is a market-driven global company that combines complex, specialty chemicals to optimize the quality, performance and value of customers' products while reducing their environmental impact. It is a leader at combining market insights with chemistry and application capabilities to deliver valuable solutions to customers in the global transportation, industrial and consumer markets. Lubrizol improves lives by acting as an essential partner in our customers' success, delivering efficiency, reliability or wellness to their end users. Technologies include lubricant additives for engine oils, driveline and other transportation-related fluids, industrial lubricants, as well as additives for gasoline and diesel fuel. In addition, Lubrizol makes ingredients and additives for home care, personal care and skin care products and specialty materials encompassing polymer and coatings technologies, along with polymer-based pharmaceutical and medical device solutions.
With headquarters in Wickliffe, Ohio, Lubrizol owns and operates manufacturing facilities in 17 countries, as well as sales and technical offices around the world. Founded in 1928, Lubrizol has approximately 8,700 employees worldwide. Revenues for 2017 were $6.3 billion. For more information, visit Lubrizol.com.
Ben Patti - (216) 447-5827
This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Lubrizol via Globenewswire
Copyright ©2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
More Latest Release >>
Eisai's Initiation of Phase III Clinical Trial of BAN2401 in Early Alzheimer's Disease
Mar 22, 2019 11:37 JST
Eisai to Present Latest Research on Alzheimer's Disease / Dementia Pipeline at the 14th International Conference on Alzheimer's & Parkinson's Diseases
Mar 22, 2019 11:23 JST
Hitachi: AI Technology for Quantifying Physical Load and Providing Effective Feedbacks Using Sensor Suit Devices
Mar 22, 2019 09:02 JST
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer's Disease
Mar 22, 2019 00:25 JST
Renault-Nissan-Mitsubishi Launches Alliance Intelligent Cloud on Microsoft Azure
Mar 21, 2019 14:57 JST
ANA Harnesses the Power of NEC's Virtual Reality Solutions in Flight Attendant Training
Mar 21, 2019 09:45 JST
Toyota and Suzuki Agree to Start Consideration Toward New Collaboration
Mar 20, 2019 17:14 JST
DOCOMO to Support 5G Game Streaming in Japan
Mar 20, 2019 16:19 JST
Hitachi Launches "Lumada Solution Hub" to Advance and Facilitate Introduction of Lumada Solutions
Mar 20, 2019 09:05 JST
DOCOMO Earns Gold Prize for Card Keitai at iF Design Award 2019
Mar 18, 2019 17:09 JST
Mitsubishi Corporation, Chubu Electric Power and HICL Infrastructure Consortium Named Preferred Bidder for Offshore Transmission Asset in the UK
Mar 18, 2019 16:50 JST
Victory for TOYOTA GAZOO Racing at Sebring
Mar 18, 2019 09:37 JST
Mitsubishi Motors TRITON Show Model is Almost Here
Mar 18, 2019 08:32 JST
DOCOMO to Test Remote-Monitoring Solution for Eldercare
Mar 14, 2019 21:32 JST
Nissan and Mitsubishi Motors to Launch New Kei Cars as Collaboration Expands
Mar 14, 2019 17:32 JST
Fujitsu Formulates "Fujitsu Group AI Commitment," Demonstrating Dedication to Safe and Secure Use of AI
Mar 13, 2019 19:38 JST
Nishi Nippon Railroad and Mitsubishi Corporation to Commence Commercial AI-Controlled Bus Transit Services in Fukuoka, Japan
Mar 13, 2019 17:14 JST
Mitsubishi Shipbuilding Holds Christening Ceremony for LPG Carrier "FUTURE ACE'
Mar 13, 2019 16:01 JST
Toyota Tsusho and NEC Conclude Contract with Uzbektelecom on Nationwide Data Communication System
Mar 13, 2019 12:39 JST
Renault, Nissan, Mitsubishi Motors Announce Intention to Create a New Alliance Operating Board
Mar 13, 2019 11:16 JST